Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million

Uppsala, Sweden, April 2, 2025. The exercise of warrants series TO 6 in Dicot Pharma was approximately 95.95 percent. Through the exercise of 115,281,330 warrants, 230,562,660 shares were subscribed for at a price of SEK 0.19 per share. Dicot Pharma will thus receive approximately SEK 43.8 million before issue costs. No subscription guarantees had been procured.

" A 96% subscription rate is a very good result in the current market and we feel great appreciation for everyone who participated and subscribed. I understand that with this we have received the second largest proceeds from an option exercise among listed Swedish small cap companies in the last six months. This again shows strong support from our shareholders and the great interest in Dicot Pharma and our drug development", comments Elin Trampe, CEO of Dicot Pharma.

Through the exercise of TO 6, Dicot Pharma will receive approximately SEK 43.8 million before issue costs. There are no costs for guarantee commitments as such agreements have not been entered into.

The exercise of the warrants changes the number of shares and share capital as follows:

	Before TO 6	TO 6	After TO 6
Shares, #	1,778,779,842	230,562,660	2,009,342,502
Share capital, SEK	12,451,458.894	1,613,938.620	14,065,397.514

For existing shareholders who have not sold or exercised their warrants TO 6, the dilution amounts to approximately 11.5 percent.

Exercised warrants TO 6 have now been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares to ordinary shares is expected to take place around April 11, 2025.

Complete terms of the warrants and more information are available at www.dicotpharma.com.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.

Attached files

Dicot_Pressrelease-2025-04-02_eng.pdf